Occurrence of Graves' Disease during Re treatment with Interferon-α2a for Chronic Hepatitis C

Abstract

The present report describes a patient who developed Graves' disease 3 months after inception of retreatment with higher doses of interferon-α2a for chronic hepatitis C, although the initial 6-month treatment caused no serious adverse reactions. Severe hyperthyroidism continued despite discontinuation of interferon-α2a, and the patient was subsequently treated with ¹³¹I. This case suggests careful evaluation of the safety of retreatment to prevent manifestation of such a complication in the retreatment of chronic hepatitis C with interferon.
(Internal Medicine 34: 1097-1100, 1995)